Company Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-27 pm EDT			5-day change	1st Jan Change
0.4376 ^USD	-8.83%		-10.18%	-43.90%

Jun. 27	Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	MT
Jun. 27	Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	CI

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Number of employees: 20

Managers	Title	Age	Since
Gil Efron CEO	Chief Executive Officer	57	18-10-10
Lior Fhima DFI	Director of Finance/CFO	-	22-11-01
Ido Morpurgo COO	Chief Operating Officer	51	20-07-31
Hadas Reuveni CTO	Chief Tech/Sci/R&D Officer	56	16-12-31
Bertrand C. Liang CTO	Chief Tech/Sci/R&D Officer	61	20-01-08
Isaac Israel BRD	Director/Board Member	44	12-09-30
Simcha Rock BRD	Director/Board Member	73	13-07-10
Yisrael Gewirtz AUD	Comptroller/Controller/Auditor	47	16-06-30
William Berlin PRN	Corporate Officer/Principal	-	-
Michael Schickler LAW	General Counsel	55	19-12-31

Members of the board	Title	Age	Since
Eric Rowinsky CHM	Chairman	67	19-10-01
Yael Margolin BRD	Director/Board Member	70	Dec. 19
Simcha Rock BRD	Director/Board Member	73	13-07-10
Ido Agmon BRD	Director/Board Member	46	16-06-26
Robert Gagnon BRD	Director/Board Member	49	21-03-02
Suzana Nahum Zilberberg BRD	Director/Board Member	53	21-05-18
Isaac Israel BRD	Director/Board Member	44	12-09-30
Ori Hershkovitz BRD	Director/Board Member	49	21-12-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	276,271,277	274,913,847 ( 99.51 %)	0	99.51 %

Name	Equities	%	Valuation
Jason Carrick 4.008 %	10,520,000	4.008 %	783 635 $
KSM Mutual Funds Ltd. 0.1421 %	372,899	0.1421 %	27 777 $
Migdal Mutual Funds Ltd. 0.0864 %	226,876	0.0864 %	16 900 $

Name	Equities	%	Valuation
Armistice Capital LLC 8.058 %	2,115,000	8.058 %	2 M $
Kingswood Wealth Advisors LLC 0.7091 %	186,100	0.7091 %	150 369 $
Morgan Stanley Capital Services LLC 0.5205 %	136,610	0.5205 %	110 381 $
Citadel Securities GP LLC 0.2211 %	58,023	0.2211 %	46 883 $
XTX Topco Ltd. 0.1109 %	29,099	0.1109 %	23 512 $
Millennium Management LLC 0.0817 %	21,438	0.0817 %	17 322 $
Virtu Financial LLC 0.0613 %	16,078	0.0613 %	12 991 $
Venture Visionary Partners LLC 0.0593 %	15,553	0.0593 %	12 567 $
Wealth Advisors of Iowa LLC 0.0544 %	14,270	0.0544 %	11 530 $
Geode Capital Management LLC 0.0483 %	12,666	0.0483 %	10 234 $

Purple Biotech Ltd.

Science Park 4 Oppenheimer Street

7670104, Rehovot

+972 3 933 3121

http://ww.purple-biotech.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.13%	122B
REGENERON PHARMACEUTICALS, INC.	+19.65%	115B
ARGENX SE	+21.22%	26.64B
BIONTECH SE	-23.84%	19.91B
GENMAB A/S	-17.47%	16.32B
WUXI APPTEC CO., LTD.	-45.95%	15.52B
BEIGENE, LTD.	-19.28%	15.49B
SAREPTA THERAPEUTICS, INC.	+63.81%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+1.94%	13.67B

Bio Therapeutic Drugs